134 related articles for article (PubMed ID: 30172110)
21. The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer.
Quiroz RV; Reutershan MH; Schneider SE; Sloman D; Lacey BM; Swalm BM; Yeung CS; Gibeau C; Spellman DS; Rankic DA; Chen D; Witter D; Linn D; Munsell E; Feng G; Xu H; Hughes JME; Lim J; Saurí J; Geddes K; Wan M; Mansueto MS; Follmer NE; Fier PS; Siliphaivanh P; Daublain P; Palte RL; Hayes RP; Lee S; Kawamura S; Silverman S; Sanyal S; Henderson TJ; Ye Y; Gao Y; Nicholson B; Machacek MR
J Med Chem; 2021 Apr; 64(7):3911-3939. PubMed ID: 33755451
[TBL] [Abstract][Full Text] [Related]
22. Development of an AlphaLISA high throughput technique to screen for small molecule inhibitors targeting protein arginine methyltransferases.
Prabhu L; Chen L; Wei H; Demir Ö; Safa A; Zeng L; Amaro RE; O'Neil BH; Zhang ZY; Lu T
Mol Biosyst; 2017 Nov; 13(12):2509-2520. PubMed ID: 29099132
[TBL] [Abstract][Full Text] [Related]
23. Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma.
Sloan SL; Renaldo KA; Long M; Chung JH; Courtney LE; Shilo K; Youssef Y; Schlotter S; Brown F; Klamer BG; Zhang X; Yilmaz AS; Ozer HG; Valli VE; Vaddi K; Scherle P; Alinari L; Kisseberth WC; Baiocchi RA
PLoS One; 2021; 16(5):e0250839. PubMed ID: 33989303
[TBL] [Abstract][Full Text] [Related]
24. Structure-Based Discovery and Biological Assays of a Novel PRMT5 Inhibitor for Non-Small Cell Lung Cancer.
Chen Y; Zhang M; Wu A; Yao X; Wang Q
Molecules; 2022 Nov; 27(21):. PubMed ID: 36364261
[TBL] [Abstract][Full Text] [Related]
25. Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.
Fedoriw A; Rajapurkar SR; O'Brien S; Gerhart SV; Mitchell LH; Adams ND; Rioux N; Lingaraj T; Ribich SA; Pappalardi MB; Shah N; Laraio J; Liu Y; Butticello M; Carpenter CL; Creasy C; Korenchuk S; McCabe MT; McHugh CF; Nagarajan R; Wagner C; Zappacosta F; Annan R; Concha NO; Thomas RA; Hart TK; Smith JJ; Copeland RA; Moyer MP; Campbell J; Stickland K; Mills J; Jacques-O'Hagan S; Allain C; Johnston D; Raimondi A; Porter Scott M; Waters N; Swinger K; Boriack-Sjodin A; Riera T; Shapiro G; Chesworth R; Prinjha RK; Kruger RG; Barbash O; Mohammad HP
Cancer Cell; 2019 Jul; 36(1):100-114.e25. PubMed ID: 31257072
[TBL] [Abstract][Full Text] [Related]
26. Arginine methyltransferase inhibitor 1 inhibits gastric cancer by downregulating eIF4E and targeting PRMT5.
Zhang B; Zhang S; Zhu L; Chen X; Zhao Y; Chao L; Zhou J; Wang X; Zhang X; Ma N
Toxicol Appl Pharmacol; 2017 Dec; 336():1-7. PubMed ID: 28987382
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and Activity of Triazole-Adenosine Analogs as Protein Arginine Methyltransferase 5 Inhibitors.
Brown T; Cao M; Zheng YG
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744905
[TBL] [Abstract][Full Text] [Related]
28. The Discovery of Selective Protein Arginine Methyltransferase 5 Inhibitors in the Management of β-Thalassemia through Computational Methods.
Pokharel B; Ravikumar Y; Rathinavel L; Chewonarin T; Pongpom M; Tipsuwan W; Koonyosying P; Srichairatanakool S
Molecules; 2024 Jun; 29(11):. PubMed ID: 38893537
[TBL] [Abstract][Full Text] [Related]
29. Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors.
Lin H; Luengo JI
Bioorg Med Chem Lett; 2019 Jun; 29(11):1264-1269. PubMed ID: 30956011
[TBL] [Abstract][Full Text] [Related]
30. Structure based discovery of novel hexokinase 2 inhibitors.
Liu Y; Li M; Zhang Y; Wu C; Yang K; Gao S; Zheng M; Li X; Li H; Chen L
Bioorg Chem; 2020 Mar; 96():103609. PubMed ID: 32007722
[TBL] [Abstract][Full Text] [Related]
31. Pharmacophore-based virtual screening, molecular docking, molecular dynamics simulation, and biological evaluation for the discovery of novel BRD4 inhibitors.
Yan G; Hou M; Luo J; Pu C; Hou X; Lan S; Li R
Chem Biol Drug Des; 2018 Feb; 91(2):478-490. PubMed ID: 28901664
[TBL] [Abstract][Full Text] [Related]
32. Synthesis, biological evaluation, drug-likeness, and in silico screening of novel benzylidene-hydrazone analogues as small molecule anticancer agents.
Alam MS; Lee DU
Arch Pharm Res; 2016 Feb; 39(2):191-201. PubMed ID: 26694484
[TBL] [Abstract][Full Text] [Related]
33. (Z)-2-(3-Chlorobenzylidene)-3,4-dihydro-N-(2-methoxyethyl)-3-oxo-2H-benzo[b][1,4]oxazine-6-carboxamide as GSK-3β inhibitor: Identification by virtual screening and its validation in enzyme- and cell-based assay.
Joshi P; Gupta M; Vishwakarma RA; Kumar A; Bharate SB
Chem Biol Drug Des; 2017 Jun; 89(6):964-971. PubMed ID: 27896926
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, and biological evaluation of novel
Xie X; Tu J; You H; Hu B
Drug Des Devel Ther; 2017; 11():1439-1451. PubMed ID: 28553074
[TBL] [Abstract][Full Text] [Related]
35. Discovery of tetrahydroisoquinolineindole derivatives as first dual PRMT5 inhibitors/hnRNP E1 upregulators: Design, synthesis and biological evaluation.
Chu WH; Yang N; Zhang JH; Li Y; Song JL; Deng ZP; Meng N; Zhang J; Zhu KK; Jiang CS
Eur J Med Chem; 2023 Oct; 258():115625. PubMed ID: 37429083
[TBL] [Abstract][Full Text] [Related]
36. Biological evaluation of 2-arylidene-4, 7-dimethyl indan-1-one (FXY-1): a novel Akt inhibitor with potent activity in lung cancer.
Rajagopalan P; Alahmari KA; Elbessoumy AA; Balasubramaniam M; Suresh R; Shariff ME; Chandramoorthy HC
Cancer Chemother Pharmacol; 2016 Feb; 77(2):393-404. PubMed ID: 26781309
[TBL] [Abstract][Full Text] [Related]
37. Virtual screening and biological characterization of novel histone arginine methyltransferase PRMT1 inhibitors.
Heinke R; Spannhoff A; Meier R; Trojer P; Bauer I; Jung M; Sippl W
ChemMedChem; 2009 Jan; 4(1):69-77. PubMed ID: 19085993
[TBL] [Abstract][Full Text] [Related]
38. 5-Benzylidene-2,4-thiazolidenedione derivatives: Design, synthesis and evaluation as inhibitors of angiogenesis targeting VEGR-2.
Bhanushali U; Rajendran S; Sarma K; Kulkarni P; Chatti K; Chatterjee S; Ramaa CS
Bioorg Chem; 2016 Aug; 67():139-47. PubMed ID: 27388635
[TBL] [Abstract][Full Text] [Related]
39. EPZ015666, a selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an antitumour effect in retinoblastoma.
Liu X; He J; Mao L; Zhang Y; Cui W; Duan S; Jiang A; Gao Y; Sang Y; Huang G
Exp Eye Res; 2021 Jan; 202():108286. PubMed ID: 33035554
[TBL] [Abstract][Full Text] [Related]
40. Exploration of cyanine compounds as selective inhibitors of protein arginine methyltransferases: synthesis and biological evaluation.
Hu H; Owens EA; Su H; Yan L; Levitz A; Zhao X; Henary M; Zheng YG
J Med Chem; 2015 Feb; 58(3):1228-43. PubMed ID: 25559100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
